Evaluation of Low-Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients

Transplantation

Volumn 99, Issue 7, 2015, Pages 1499-1505

  Gabardi, Steven ^a,b   Asipenko, Natalya ^c   Fleming, James ^d   Lor, Kevin ^e   McDevitt Potter, Lisa ^f   Mohammed, Anisa ^a   Rogers, Christin ^b   Tichy, Eric M ^g   Weng, Renee ^h   Lee, Ruth Ann ⁱ  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f TUFTS MEDICAL CENTER   (United States)

^g YALE NEW HAVEN HOSPITAL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VALGANCICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAFT FAILURE; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RATE; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LEUKOPENIA; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; ACUTE DISEASE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ODDS RATIO; OPPORTUNISTIC INFECTIONS; PREVALENCE; RETROSPECTIVE STUDY; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; VIROLOGY;

ACUTE DISEASE; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCOMPROMISED HOST; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; OPPORTUNISTIC INFECTIONS; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84940720773     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000570     Document Type: Article

References (29)

1. De Keyzer K, Van Laecke S, Peeters P, Vanholder R. Human cytomegalovirus and kidney transplantation: a clinician's update. Am J Kidney Dis 2011;58:118.
2. Fisher RA. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation. Transpl Infect Dis 2009;11:195.
3. Razonable RR. Strategies for managing cytomegalovirus in transplant recipients. Expert Opin Pharmacother 2010;11:1983.
4. Le Page AK, Jager MM, Kotton CN, Simoons-Smit A, Rawlinson WD. International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines. Transplantation 2013;95:1455.
5. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010;89:779.
6. Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013;13Suppl 4:93.
7. Manuel O, Perrottet N, Pascual M. Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation Expert Rev Anti Infect Ther 2011;9:955.
8. Bulletin Current Drug Shortage: Ganciclovir Capsules. 2012. (Accessed December 5, 2012, at http://www.ashp.org/DrugShortages/Current/bulletin.aspx?id=539.).
9. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010;10:1228.
10. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000;44:2811.
11. Food and Drug Administration. FDA Approved Drug Products. 2012. (Accessed November 5, 2012, at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label-ApprovalHistory#labelinfo.).
12. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003;3:731.
13. Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy 2004;24:1323.
14. Keven K, Basu A, Tan HP, et al. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Transplant Proc 2004;36:3107.
15. Park JM, Lake KD, Arenas JD, Fontana RJ. Efficacy and safety of lowdose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients Liver Transplant 2006;12:112.
16. Walker JK, Scholz LM, Scheetz MH, et al. Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction. Transplantation 2007;83:874.
17. Avidan YP, Paul M, Rahamimov R, et al. Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation J Infect 2008;57:236.
18. Brady RL, Green K, Frei C, Maxwell P Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis 2009;11:106.
19. Luan FL, Kommareddi M, Ojo AO. Impact of cytomegalovirus disease in D+/R? kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis. Am J Transplant 2011;11:1936.
20. Weng FL, Patel AM, Wanchoo R, et al. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants. Transplantation 2007;83:290.
21. Chamberlain CE, Penzak SR, Alfaro RM, et al. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Am J Transplant 2008;8:1297.
22. Manuel O, Pascual M, Perrottet N, et al. Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study. Clin Transplant 2010;24:794.
23. Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. Clin Infect Dis 2011;52:313.
24. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 2005;40:704.
25. Humar A, Mazzulli T, Moussa G, et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R? transplant recipients. Am J Transplant 2005;5:1065.
26. Thomson Reuters Micromedex Clinical Evidence Solutions [Internet]. Thomson Reuters; c2014. RED BOOK Drug References; c2014 [cited September 15, 2014]. Available from: http://thomsonreuters.com/productsservices/healthcare/healthcareproducts/clinicaldecisupport/micromedexclinicalevidencesols/medsafetysolutions/redbook/. (Accessed at.
27. Prendergast MB, Gaston RS. Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation. Clin J Am Soc Nephrol 2010;5:1305.
28. Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004;77:769.
29. Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012;93:1075.